J Drugs Dermatol. 2024 Feb 1;23(2):54-60. doi: 10.36849/JDD.7691.
Cutaneous squamous cell carcinoma (cSCC) is a growing health concern with a rapidly increasing incidence. Disease-specific mortality is typically preceded by a metastasis, but current staging systems have significant limitations in predicting this event. The 40-gene expression profile (40-GEP) test is a validated method of further stratifying patients based on the risk of regional or distant metastasis, but limited guidelines exist for incorporating this test into clinical practice.
To review the available literature on the use of gene expression profile (GEP) testing to assess prognosis in cSCC and create consensus statements to guide dermatology clinicians on its use.
A comprehensive literature search of PubMed, EMBASE, and Scopus was completed for English-language original research articles on the use of GEP testing to assess cSCC prognosis. A panel of 8 dermatologists with significant expertise in diagnosing and managing cSCC gathered to review the articles and create consensus statements. A modified Delphi process was used to approve each statement and a strength of recommendation was assigned using the Strength of Recommendation Taxonomy (SORT) criteria.
The literature search produced 157 articles that met the search criteria. A thorough screening of the studies for relevance to the research question resulted in 21 articles that were distributed to the panelists for review prior to the roundtable discussion. The panel unanimously voted to adopt 7 consensus statements and recommendations, 6 of which were given a strength of "A" and 1 of which was given a strength of "C".
The 40-GEP test provides accurate and independent prognostic information beyond standard staging systems that only incorporate pathologic data. Incorporation of GEP testing into national guidelines can help further stratify patients based on risk of metastasis and thus may improve morbidity and mortality. J Drugs Dermatol. 2023;22(12):54-60. doi:10.36849/JDD.7691.
皮肤鳞状细胞癌（cSCC）是一个日益严重的健康问题，其发病率正在迅速上升。疾病特异性死亡率通常先于转移，但目前的分期系统在预测这一事件方面存在显著局限性。40 个基因表达谱（40-GEP）检测是一种基于区域性或远处转移风险进一步分层患者的有效方法，但将该检测纳入临床实践的指南有限。
回顾评估 cSCC 预后的基因表达谱（GEP）检测的可用文献，并制定共识声明，指导皮肤科临床医生使用该检测。
对评估 cSCC 预后的 GEP 检测的英文原始研究文献进行了全面的 PubMed、EMBASE 和 Scopus 文献检索。一个由 8 名在诊断和治疗 cSCC 方面具有丰富专业知识的皮肤科医生组成的小组聚集在一起，审查这些文章并制定共识声明。使用改良 Delphi 过程来批准每个声明，并使用推荐分级的强度（SORT）标准来分配推荐强度。
文献检索产生了 157 篇符合检索标准的文章。对研究相关性进行了彻底筛选，最终确定了 21 篇文章分发给小组讨论员进行讨论。专家组一致投票通过了 7 项共识声明和建议，其中 6 项的推荐强度为“A”，1 项的推荐强度为“C”。
40-GEP 检测提供了比仅包含病理数据的标准分期系统更准确和独立的预后信息。将 GEP 检测纳入国家指南可以帮助根据转移风险进一步分层患者，从而可能改善发病率和死亡率。J 皮肤病药物学杂志。2023；22（12）：54-60。doi：10.36849/JDD.7691.
